New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

 
• By Ahmet Sevindik
  
Diabetes-Concept_56048224_1200x675
Biosimilar insulin glargine could lead to changes in Turkish diabetes market

More from Manufacturing

More from Business